NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...
For the growing number of multi-indication medicines, challenges arise in assessing and paying for value across medicine indications with a uniform price (see our previous report and further ...
This blog by Martina Garau (OHE) and Dr. Tina Wang (CIRS) provides a framework to navigate key aims, challenges and opportunities offered by recent initiatives and reflects on future prospects.
Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...
Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of Economic Research ...
Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public ...
Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It Make to Decisions About Life-Extending Treatments? Chris Skedgel ...
Ellie is on the fellowship programme with City University, studying Economic Evaluation in Healthcare. She has a BSc in Biochemistry from the University of Bath and worked in the pharmaceutical ...
Siva is chief analyst in the policy team, leading on projects covering NHS funding, finances, productivity and performance. Before joining the Fund in 2017, Siva was head of analysis at NHS Providers ...
Donna is Professor of Health Economics at the School of Health and Related Research at the University of Sheffield.
Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens ...